Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Need for drug delivery systems 1
Published on October 31, 2019 16 min
Other Talks in the Series: Drug Delivery
Mucoadhesive drug delivery systems
- Dr. Panoraia I. Siafaka
- European University Cyprus, Cyprus
Ocular drug delivery
- Prof. Emily Dosmar
- Rose-Hulman Institute of Technology, USA
Hello, my name is Ana Catarina Silva and I'm an Assistant Professor of University Fernando Pessoa, an invited Professor at the Faculty of Pharmacy from Porto, Portugal. This is the first part of the talk on the "Need for Drug Delivery Systems" and the second part will be delivered by my colleague Professor Joao Nuno Moreira.
I will start my presentation with an explanation about the general limitations of the conventional pharmaceutical dosage forms and some of the strategies used for improved drug bioavailability. Afterwards, I'll provide an overview about the drug delivery systems and in particular, the most studied nanosystems. Finally, I'll end with some concluding remarks.
Among the general limitations of conventional pharmaceutical dosage forms are; the fast drug elimination from the body which leads to unfavorable pharmacokinetics, the need to perform repeated administration to achieve constant drug plasma concentration that can originate problems of patient compliance. The lack on the drug selectivity for target tissues that is responsible for adverse and sub-therapeutic effects and the occurrence of drug degradation and toxicity in the body that can originate in tissue damage. All these limitations originate bioavailability problems.
Other limitations of the conventional pharmaceutical dosage forms are related to the frequent synthesis of new drug molecules that belong to the BCS classes II and IV, presenting lipophilic characteristics and low solubility which may precipitate in aqueous media and also to the BCS class III that have high solubility and poor intestinal permeability. These drugs present difficulties of formulation and therefore bioavailability problems.